Conference Coverage

Standardization of the Discharge Process for Inpatient Hematology and Oncology

Abstract: 2018 AVAHO Meeting


 

Purpose/Rationale: To standardize the discharge process for the hematology/oncology inpatient service at Hines VA Hospital to improve the transition of care

Background: The landmark 1999 report from the Institute of Medicine, To Err is Human, identified the impact of medical error on mortality and morbidity. Medical errors tend to occur during transitions of care. At Hines VA Hospital, a multidisciplinary team delivers specialized care to veterans on the hematology/oncology service. However, resident physicians staffing the inpatient hematology/oncology service may be unfamiliar with the unique needs of the service and population. Currently there is no standardized discharge process in place. Prior studies have demonstrated improved outcomes following standardization of the discharge process for hematology patients. The authors aim to develop and implement a standardized discharge process to minimize risk for medical error.

Method/Approach: A multidisciplinary team of hematology and oncology staff was formed, including attending physicians, fellows, residents, advanced practice nurses, registered nurses, clinical pharmacists, and patient care coordinators, and several interviews were conducted. A standardized discharge process was developed in the form of guidelines and expectations. These include an explanation of unique features of the hematology/oncology service and expectations of medication reconciliation with emphasis placed on antiemetics, antimicrobial prophylaxis, and bowel regimen when appropriate, ambulatory hematology/oncology follow up within 1-2 weeks, primary care followup, communication with ambulatory hematology/oncology physician, written discharge instructions, and bedside teaching when appropriate. The standardized process will be taught to rotating resident physicians in the form of both online orientation and an in-person orientation. Outcome measures were identified including key components of medication reconciliation, time to hematology & oncology clinic visit, time to primary care visit, communication of discharge with outpatient hematology/oncology physician, and 30-day readmission rate.

Conclusions: All patients discharged during the twomonth period prior to and all patients discharged after the implementation of the standardized process will be reviewed; the above-mentioned variables will be recorded. Outcomes will be compared. Interim multidisciplinary team focus group meetings will be held every quarter to review and refine the process.

Recommended Reading

Open Clinical Trials for Patients With Renal Cell Carcinoma (FULL)
AVAHO
VA and NCI Join to Provide Leading-Edge Cancer Treatment
AVAHO
FDA warns against azithromycin in blood or lymph node cancers
AVAHO
New chronic lymphocytic leukemia guidelines from the UK
AVAHO
Could An Antibiotic Be the Next Great Oncologic Drug?
AVAHO
Abstracts Presented at the 2018 AVAHO Annual Meeting (Digital Edition)
AVAHO
Cardiovascular Effects of Tyrosine Kinase Inhibitors in Advanced Renal Cell Carcinoma (RCC) Patients at VA San Diego Healthcare System (VASDHS)
AVAHO
Implementation of a Hematology VA-ECHO Program
AVAHO
Impact of an Educational Seminar Series for VA Providers in Personalized Cancer Care Across Hematologic and Solid Tumors
AVAHO
STORM trial shows response in penta-refractory myeloma
AVAHO